aspartic acid has been researched along with Bipolar Disorder in 113 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nineteen subjects with bipolar disorder in remission, who reported subjective cognitive deficits, were treated with open-label galantamine-ER 8-24 mg/day for 4 months." | 9.14 | Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study. ( Deckersbach, T; Iosifescu, DV; Moore, CM; Nierenberg, AA; Ostacher, MJ; Sachs, GS; Tilley, CA, 2009) |
| "We investigated the relationship between brain lithium levels and the metabolites N-acetyl aspartate (NAA) and myo-inositol (myo-Ino) in the anterior cingulate cortex of a group of older adults with bipolar disorder (BD)." | 9.13 | Brain lithium, N-acetyl aspartate and myo-inositol levels in older adults with bipolar disorder treated with lithium: a lithium-7 and proton magnetic resonance spectroscopy study. ( Berlow, YA; Finn, CT; Forester, BP; Moore, CM; Renshaw, PF; Wardrop, M, 2008) |
| "This project was designed to compare differences in brain proton spectra between children and adolescents with bipolar disorder (BPD) and gender and age-matched normal controls, and to measure changes in myo-inositol levels following lithium therapy, utilizing in vivo proton magnetic resonance spectroscopy (1H MRS)." | 9.09 | Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. ( Belin, T; Davanzo, P; McCracken, J; Oshiro, T; Strober, M; Thomas, MA; Yue, K, 2001) |
| " However, there were no associations between NAA/Cr, Glu/Cr, or Gln/Cr and either depression severity or lamotrigine treatment." | 7.91 | Lamotrigine Therapy and Biomarkers of Cerebral Energy Metabolism in Older Age Bipolar Depression. ( Forester, BP; Harper, DG; Jensen, E; Mellen, EJ; Ravichandran, C; Silveri, M, 2019) |
| "As choline is a marker of membrane phospholipid metabolism, the elevated choline in patients may indicate increased membrane breakdown in the brain regions examined." | 5.35 | Increased choline-containing compounds in the orbitofrontal cortex and hippocampus in euthymic patients with bipolar disorder: a proton magnetic resonance spectroscopy study. ( Hall, GB; MacQueen, GM; Milne, AM; Senaratne, R, 2009) |
| "Nineteen subjects with bipolar disorder in remission, who reported subjective cognitive deficits, were treated with open-label galantamine-ER 8-24 mg/day for 4 months." | 5.14 | Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study. ( Deckersbach, T; Iosifescu, DV; Moore, CM; Nierenberg, AA; Ostacher, MJ; Sachs, GS; Tilley, CA, 2009) |
| "We investigated the relationship between brain lithium levels and the metabolites N-acetyl aspartate (NAA) and myo-inositol (myo-Ino) in the anterior cingulate cortex of a group of older adults with bipolar disorder (BD)." | 5.13 | Brain lithium, N-acetyl aspartate and myo-inositol levels in older adults with bipolar disorder treated with lithium: a lithium-7 and proton magnetic resonance spectroscopy study. ( Berlow, YA; Finn, CT; Forester, BP; Moore, CM; Renshaw, PF; Wardrop, M, 2008) |
| "This project was designed to compare differences in brain proton spectra between children and adolescents with bipolar disorder (BPD) and gender and age-matched normal controls, and to measure changes in myo-inositol levels following lithium therapy, utilizing in vivo proton magnetic resonance spectroscopy (1H MRS)." | 5.09 | Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. ( Belin, T; Davanzo, P; McCracken, J; Oshiro, T; Strober, M; Thomas, MA; Yue, K, 2001) |
| "Response to lithium maintenance varies widely across patients with bipolar disorder (BD)." | 4.31 | Elevated choline in dorsolateral prefrontal cortex of lithium responders with bipolar I disorder. ( Deep, R; Khandelwal, SK; Kumaran, SS; Mahal, P, 2023) |
| " However, there were no associations between NAA/Cr, Glu/Cr, or Gln/Cr and either depression severity or lamotrigine treatment." | 3.91 | Lamotrigine Therapy and Biomarkers of Cerebral Energy Metabolism in Older Age Bipolar Depression. ( Forester, BP; Harper, DG; Jensen, E; Mellen, EJ; Ravichandran, C; Silveri, M, 2019) |
| "Previous studies reported decreased N-acetyl aspartate and increased Glx (the sum of glutamate plus glutamine) in bipolar disorder." | 3.85 | Hippocampal neurochemical markers in bipolar disorder patients following the first-manic episode: A prospective 12-month proton magnetic resonance spectroscopy study. ( Bond, DJ; Bücker, J; Kapczinski, F; Kozicky, JM; MacMillan, EL; Muralidharan, K; Rosa, AR; Silveira, LE; Yatham, LN, 2017) |
| "We wished to determine whether decreases in N-acetyl aspartate (NAA) and increases in myoinositol (mI) concentrations as a ratio of creatine (Cr) occurred in the dorsolateral prefrontal cortex (DLPFC) of pediatric offspring of parents with bipolar disorder (BD) and a healthy comparison group (HC) over a 5-year period using proton magnetic resonance spectroscopy ((1)H-MRS)." | 3.79 | Prospective neurochemical characterization of child offspring of parents with bipolar disorder. ( Adleman, NE; Bararpour, L; Chang, KD; Howe, M; Jo, B; Kelley, RG; Singh, MK; Spielman, D, 2013) |
| "The few studies applying single-voxel ¹H spectroscopy in children and adolescents with bipolar disorder (BD) have reported low N-acetyl-aspartate (NAA) levels in the dorsolateral prefrontal cortex (DLPFC), and high myo-inositol / phosphocreatine plus creatine (PCr+Cr) ratios in the anterior cingulate." | 3.77 | Lower N-acetyl-aspartate levels in prefrontal cortices in pediatric bipolar disorder: a ¹H magnetic resonance spectroscopy study. ( Caetano, SC; Chen, HH; Fonseca, M; Hatch, JP; Hunter, K; Lafer, B; Nicoletti, M; Olvera, RL; Pliszka, SR; Sanches, M; Soares, JC; Stanley, JA, 2011) |
| "We aimed to compare concentrations of N-acetyl aspartate, myo-inositol, and other neurometabolites in the cerebellar vermis of offspring at risk for bipolar disorder (BD) and healthy controls to examine whether changes in these neuronal metabolite concentrations occur in at-risk offspring prior to the onset of mania." | 3.77 | Neurochemical deficits in the cerebellar vermis in child offspring of parents with bipolar disorder. ( Acquaye, T; Adams, E; Chang, KD; Howe, M; Kelley, R; Libby, A; Reiss, A; Singh, MK; Spielman, D, 2011) |
| "Glutamine/glutamate ratio was significantly higher in ACC and POC in bipolar disorder, but not schizophrenia, compared with healthy control subjects." | 3.74 | Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. ( Cohen, BM; Jensen, JE; Lundy, M; Öngür, D; Prescot, AP; Renshaw, PF; Stork, C, 2008) |
| "An [1H]-MRS was used to measure levels of GABA, of the combined concentration of Glu and glutamine (Gln), and of N-acetylaspartate (NAA) in occipital cortex in medication-free, fully recovered subjects with a history of recurrent unipolar depression (n = 15), bipolar disorder (n = 16), and a group of healthy controls (n = 18)." | 3.74 | Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. ( Ashworth, F; Bhagwagar, Z; Cowen, PJ; Evans, J; Jezzard, P; Matthews, PM; Sule, A; Wylezinska, M, 2007) |
| "The upregulation of the initiating step of the kynurenine pathway was demonstrated in postmortem anterior cingulated cortex from individuals with schizophrenia and bipolar disorder." | 3.74 | Tryptophan breakdown pathway in bipolar mania. ( Kim, YK; Leonard, BE; Myint, AM; Park, SH; Scharpé, S; Steinbusch, HW; Verkerk, R, 2007) |
| "Compared to controls, schizophrenia and bipolar patients presented decreased NAA to creatine ratios, while only the schizophrenia group showed an increase in CSF in the dorsolateral prefrontal region." | 3.74 | Dorsolateral prefrontal N-acetyl-aspartate concentration in male patients with chronic schizophrenia and with chronic bipolar disorder. ( Benito, C; Desco, M; Leal, I; Molina, V; Palomo, T; Rebolledo, R; Reig, S; Sánchez, J; Sanz, J; Sarramea, F, 2007) |
| "The authors examined the levels of NAA, creatine plus phosphocreatine, and choline-containing molecules in the left dorsolateral prefrontal cortex of 14 bipolar disorder patients (mean age=15." | 3.73 | Reduced NAA levels in the dorsolateral prefrontal cortex of young bipolar patients. ( Axelson, D; Birmaher, B; Brambilla, P; Keshavan, MS; Nicoletti, MA; Ramos, RT; Ryan, N; Sassi, RB; Soares, JC; Stanley, JA, 2005) |
| "Based on earlier structural and functional neuroimaging studies, we specifically wanted to assess N-acetylaspartate (NAA), choline-containing compounds (CHO), and creatine+phosphocreatine (CRE) levels in brain hippocampus previously demonstrated to be involved in the pathophysiology of bipolar disorder which have not been evaluated in first-episode patients." | 3.73 | Hippocampal 1H MRS in first-episode bipolar I patients. ( Atmaca, M; Ogur, E; Ozdemir, H; Poyraz, AK; Tezcan, E; Yildirim, H, 2006) |
| "The patients with bipolar disorder showed significantly higher anterior cingulate myo-inositol/creatine-phosphocreatine and myo-inositol (mmol/liter) levels than the patients with intermittent explosive disorder and the normal comparison subjects." | 3.72 | Proton magnetic resonance spectroscopy of bipolar disorder versus intermittent explosive disorder in children and adolescents. ( Barnett, S; Belin, T; Davanzo, P; McCracken, J; Mintz, J; Santoro, E; Thomas, MA; Venkatraman, TN; Yue, K, 2003) |
| "Twenty-six adolescents with bipolar depression participated in an 8-week placebo-controlled trial of QUET monotherapy." | 2.77 | Neurometabolite effects of response to quetiapine and placebo in adolescents with bipolar depression. ( Adler, C; Bryan, H; Chang, K; Chu, WJ; Delbello, M; Eliassen, J; Garrett, A; Howe, M; Kelley, R; Mills, N; Spielman, D; Strakowski, SM, 2012) |
| " However, the study suggests that chronic administration of sodium valproate to patients does not lead to similar changes in NAA concentrations." | 2.71 | Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. ( Asghar, SJ; Hanstock, CC; O'Donnell, T; Silverstone, PH; Ulrich, M; Wu, RH, 2003) |
| "Patients with bipolar depression underwent two-dimensional proton magnetic resonance spectroscopy of the anterior cingulate at baseline (n = 15) and after 12 weeks of lamotrigine treatment (n = 10)." | 1.42 | N-acetylaspartate normalization in bipolar depression after lamotrigine treatment. ( Abulseoud, OA; Baruth, JM; Choi, DS; Croarkin, PE; Frye, MA; Port, JD; Thomas, MA, 2015) |
| " Whilst the mechanism by which GSH exerts any clinical effect is unknown it has been proposed that it involves the bolstering of antioxidant defences by increasing the bioavailability of GSH, which in turn reverses clinical symptoms of depression." | 1.39 | In vivo glutathione levels in young persons with bipolar disorder: a magnetic resonance spectroscopy study. ( Duffy, S; Hermens, DF; Hickie, IB; Lagopoulos, J; Naismith, SL; Scott, E; Tobias-Webb, J; White, D, 2013) |
| "Alcoholism is highly prevalent among bipolar disorder (BD) patients, and its presence is associated with a worse outcome and refractoriness to treatment of the mood disorder." | 1.36 | Bipolar disorder comorbid with alcoholism: a 1H magnetic resonance spectroscopy study. ( Chen, HH; Hatch, JP; Lafer, B; Monkul, ES; Nery, FG; Nicoletti, MA; Soares, JC; Stanley, JA, 2010) |
| "As choline is a marker of membrane phospholipid metabolism, the elevated choline in patients may indicate increased membrane breakdown in the brain regions examined." | 1.35 | Increased choline-containing compounds in the orbitofrontal cortex and hippocampus in euthymic patients with bipolar disorder: a proton magnetic resonance spectroscopy study. ( Hall, GB; MacQueen, GM; Milne, AM; Senaratne, R, 2009) |
| "Fourteen patients with chronic paranoid schizophrenia, 17 euthymic type I bipolar patients with no previous history of psychotic symptoms and 15 healthy controls were included, most of them were female." | 1.35 | Biochemical changes in the cingulum in patients with schizophrenia and chronic bipolar disorder. ( Albert, C; Cabaleiro, F; de Luxan, A; Galán, R; Leal, I; Luque, R; Molina, V; Osuna, MI; Prieto, D; Ruiz, M; Sarramea Crespo, F; Sau, P, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (4.42) | 18.7374 |
| 1990's | 4 (3.54) | 18.2507 |
| 2000's | 55 (48.67) | 29.6817 |
| 2010's | 43 (38.05) | 24.3611 |
| 2020's | 6 (5.31) | 2.80 |
| Authors | Studies |
|---|---|
| Magnotta, VA | 1 |
| Xu, J | 2 |
| Fiedorowicz, JG | 1 |
| Williams, A | 1 |
| Shaffer, J | 1 |
| Christensen, G | 1 |
| Long, JD | 1 |
| Taylor, E | 1 |
| Sathyaputri, L | 1 |
| Richards, JG | 1 |
| Harmata, G | 1 |
| Wemmie, J | 1 |
| Chabert, J | 1 |
| Allauze, E | 1 |
| Pereira, B | 1 |
| Chassain, C | 1 |
| De Chazeron, I | 1 |
| Rotgé, JY | 1 |
| Fossati, P | 1 |
| Llorca, PM | 1 |
| Samalin, L | 1 |
| Mahal, P | 3 |
| Deep, R | 3 |
| Kumaran, SS | 3 |
| Khandelwal, SK | 3 |
| Lai, S | 4 |
| Zhong, S | 5 |
| Shan, Y | 1 |
| Wang, Y | 5 |
| Chen, G | 4 |
| Luo, X | 1 |
| Chen, F | 1 |
| Zhang, Y | 3 |
| Shen, S | 1 |
| Huang, H | 1 |
| Ning, Y | 1 |
| Jia, Y | 5 |
| Mansur, RB | 1 |
| Subramaniapillai, M | 1 |
| Lee, Y | 1 |
| Pan, Z | 1 |
| Carmona, NE | 1 |
| Shekotikhina, M | 1 |
| Iacobucci, M | 1 |
| Rodrigues, N | 1 |
| Nasri, F | 1 |
| Rosenblat, JD | 1 |
| Brietzke, E | 1 |
| Cosgrove, VE | 1 |
| Kramer, NE | 1 |
| Suppes, T | 1 |
| Newport, J | 1 |
| Hajek, T | 3 |
| McIntyre, RS | 1 |
| Chen, J | 1 |
| Zou, S | 1 |
| Qu, Y | 1 |
| Zhang, C | 1 |
| Tang, X | 1 |
| Ren, Y | 1 |
| Soeiro-de-Souza, MG | 2 |
| Scotti-Muzzi, E | 1 |
| Fernandes, F | 1 |
| De Sousa, RT | 1 |
| Leite, CC | 1 |
| Otaduy, MC | 1 |
| Machado-Vieira, R | 3 |
| Bond, DJ | 2 |
| Silveira, LE | 2 |
| MacMillan, EL | 2 |
| Torres, IJ | 1 |
| Lang, DJ | 1 |
| Su, W | 1 |
| Honer, WG | 1 |
| Lam, RW | 1 |
| Yatham, LN | 3 |
| Huber, RS | 1 |
| Kondo, DG | 1 |
| Shi, XF | 1 |
| Prescot, AP | 3 |
| Clark, E | 1 |
| Renshaw, PF | 6 |
| Yurgelun-Todd, DA | 1 |
| Liao, X | 3 |
| Huang, J | 1 |
| Zhang, S | 1 |
| Sun, Y | 1 |
| Zhao, H | 1 |
| Szulc, A | 1 |
| Wiedlocha, M | 1 |
| Waszkiewicz, N | 1 |
| Galińska-Skok, B | 1 |
| Marcinowicz, P | 1 |
| Gierus, J | 1 |
| Mosiolek, A | 1 |
| Li, C | 1 |
| Wang, A | 1 |
| Wang, C | 1 |
| Ramamurthy, J | 1 |
| Zhang, E | 1 |
| Guadagno, E | 1 |
| Trakadis, Y | 1 |
| Otaduy, MCG | 1 |
| Moreno, RA | 1 |
| Nery, FG | 4 |
| Leite, C | 1 |
| Lafer, B | 6 |
| Liu, T | 2 |
| Bustillo, JR | 1 |
| Jones, T | 1 |
| Qualls, C | 1 |
| Chavez, L | 1 |
| Lin, D | 1 |
| Lenroot, RK | 1 |
| Gasparovic, C | 1 |
| Mellen, EJ | 1 |
| Harper, DG | 1 |
| Ravichandran, C | 1 |
| Jensen, E | 1 |
| Silveri, M | 1 |
| Forester, BP | 2 |
| Borgelt, L | 1 |
| Strakowski, SM | 11 |
| DelBello, MP | 10 |
| Weber, W | 2 |
| Eliassen, JC | 2 |
| Komoroski, RA | 1 |
| Chu, WJ | 6 |
| Welge, JA | 1 |
| Blom, TJ | 1 |
| Rummelhoff, E | 2 |
| Tallman, M | 1 |
| Lee, JH | 3 |
| Adler, CM | 8 |
| Lewandowski, KE | 2 |
| Du, F | 2 |
| Fan, X | 1 |
| Chen, X | 1 |
| Huynh, P | 1 |
| Öngür, D | 5 |
| Weber, WA | 2 |
| Jarvis, KB | 2 |
| Welge, J | 2 |
| Kim, MJ | 2 |
| Norris, MM | 1 |
| Dydak, U | 1 |
| Harezlak, J | 1 |
| Nixon, J | 1 |
| Dzemidzic, M | 1 |
| Gunn, AD | 1 |
| Karne, HS | 1 |
| Anand, A | 1 |
| Godlewska, BR | 1 |
| Yip, SW | 1 |
| Near, J | 1 |
| Goodwin, GM | 1 |
| Cowen, PJ | 2 |
| Gigante, AD | 1 |
| Singh, MK | 2 |
| Jo, B | 1 |
| Adleman, NE | 1 |
| Howe, M | 5 |
| Bararpour, L | 1 |
| Kelley, RG | 1 |
| Spielman, D | 6 |
| Chang, KD | 3 |
| Calkin, C | 1 |
| Blagdon, R | 1 |
| Slaney, C | 1 |
| Alda, M | 2 |
| Bitter, SM | 1 |
| Zhao, G | 1 |
| Xiang, Q | 1 |
| Ling, X | 1 |
| Liu, S | 1 |
| Huang, L | 1 |
| Sperry, SH | 1 |
| Cohen, BM | 4 |
| Sehovic, S | 1 |
| Goldbach, JR | 1 |
| Atagün, MI | 1 |
| Şıkoğlu, EM | 1 |
| Can, SS | 1 |
| Karakaş-Uğurlu, G | 1 |
| Ulusoy-Kaymak, S | 1 |
| Çayköylü, A | 1 |
| Algın, O | 1 |
| Phillips, ML | 1 |
| Moore, CM | 3 |
| Croarkin, PE | 1 |
| Thomas, MA | 4 |
| Port, JD | 2 |
| Baruth, JM | 1 |
| Choi, DS | 1 |
| Abulseoud, OA | 1 |
| Frye, MA | 3 |
| Ehrlich, A | 1 |
| Schubert, F | 2 |
| Pehrs, C | 1 |
| Gallinat, J | 1 |
| Kozicky, JM | 1 |
| Muralidharan, K | 1 |
| Bücker, J | 1 |
| Rosa, AR | 1 |
| Kapczinski, F | 3 |
| Aydin, B | 1 |
| Yurt, A | 1 |
| Gökmen, N | 1 |
| Renshaw, P | 1 |
| Olson, D | 1 |
| Yildiz, A | 1 |
| Lotfi, M | 1 |
| Shafiee, S | 1 |
| Ghanizadeh, A | 1 |
| Sigaroudi, MO | 1 |
| Razeghian, L | 1 |
| Tan, HZ | 1 |
| Li, H | 2 |
| Liu, CF | 1 |
| Guan, JT | 1 |
| Guo, XB | 1 |
| Wen, CH | 1 |
| Ou, SM | 1 |
| Zhang, YN | 1 |
| Zhang, J | 3 |
| Xu, CT | 1 |
| Shen, ZW | 1 |
| Wu, RH | 2 |
| Wang, XQ | 1 |
| Xu, H | 1 |
| Guan, J | 1 |
| Xu, C | 1 |
| Shen, Z | 1 |
| Xiao, B | 1 |
| Liang, C | 1 |
| Chen, K | 1 |
| Wu, R | 1 |
| Wang, B | 1 |
| Jensen, JE | 2 |
| Stork, C | 1 |
| Lundy, M | 1 |
| Scherk, H | 5 |
| Backens, M | 5 |
| Zill, P | 1 |
| Schneider-Axmann, T | 5 |
| Wobrock, T | 2 |
| Usher, J | 4 |
| Reith, W | 5 |
| Falkai, P | 5 |
| Möller, HJ | 1 |
| Bondy, B | 1 |
| Gruber, O | 5 |
| Finn, CT | 1 |
| Berlow, YA | 1 |
| Wardrop, M | 1 |
| Patel, NC | 3 |
| Cecil, KM | 6 |
| Dickstein, DP | 2 |
| Towbin, KE | 2 |
| Van Der Veen, JW | 2 |
| Rich, BA | 1 |
| Brotman, MA | 1 |
| Knopf, L | 2 |
| Onelio, L | 1 |
| Pine, DS | 2 |
| Leibenluft, E | 2 |
| Michael, N | 2 |
| Erfurth, A | 2 |
| Pfleiderer, B | 2 |
| Senaratne, R | 1 |
| Milne, AM | 1 |
| MacQueen, GM | 2 |
| Hall, GB | 1 |
| Stanley, JA | 8 |
| Chen, HH | 4 |
| Hatch, JP | 5 |
| Nicoletti, MA | 5 |
| Monkul, ES | 2 |
| Soares, JC | 8 |
| Iosifescu, DV | 1 |
| Deckersbach, T | 1 |
| Tilley, CA | 1 |
| Ostacher, MJ | 1 |
| Sachs, GS | 2 |
| Nierenberg, AA | 1 |
| Rouse, ED | 1 |
| Olson, DP | 1 |
| Kemmer, C | 3 |
| Singh, M | 1 |
| Adleman, N | 2 |
| Alegria, D | 1 |
| Reiss, A | 4 |
| Chang, K | 3 |
| Reynolds, LM | 2 |
| Reynolds, GP | 2 |
| Sumegi, A | 1 |
| Halasz, S | 1 |
| Kliment, E | 1 |
| Caetano, SC | 4 |
| Olvera, RL | 2 |
| Sanches, M | 1 |
| Nicoletti, M | 3 |
| Fonseca, M | 2 |
| Hunter, K | 2 |
| Pliszka, SR | 2 |
| Libby, A | 1 |
| Adams, E | 1 |
| Acquaye, T | 1 |
| Kelley, R | 2 |
| Hasan, A | 1 |
| Ekawardhani, S | 1 |
| Schmitt, A | 1 |
| Meyer, J | 2 |
| Shahana, N | 1 |
| Delbello, M | 2 |
| Jarvis, K | 1 |
| Fleck, D | 1 |
| Strakowski, S | 1 |
| Adler, C | 2 |
| Bauer, M | 1 |
| Pfennig, A | 1 |
| Cullis, J | 1 |
| Ploch, J | 1 |
| O'Donovan, C | 1 |
| Bohner, G | 1 |
| Klingebiel, R | 1 |
| Young, LT | 1 |
| Garrett, A | 1 |
| Mills, N | 1 |
| Bryan, H | 1 |
| Eliassen, J | 1 |
| Lagopoulos, J | 2 |
| Hermens, DF | 1 |
| Tobias-Webb, J | 1 |
| Duffy, S | 1 |
| Naismith, SL | 1 |
| White, D | 1 |
| Scott, E | 1 |
| Hickie, IB | 1 |
| Morey, R | 1 |
| Silverstone, PH | 1 |
| O'Donnell, T | 1 |
| Ulrich, M | 1 |
| Asghar, SJ | 1 |
| Hanstock, CC | 1 |
| Ohrmann, P | 1 |
| Gössling, M | 1 |
| Arolt, V | 1 |
| Heindel, W | 1 |
| Deicken, RF | 2 |
| Pegues, MP | 1 |
| Anzalone, S | 1 |
| Feiwell, R | 2 |
| Soher, B | 1 |
| Bertolino, A | 2 |
| Frye, M | 1 |
| Callicott, JH | 1 |
| Mattay, VS | 1 |
| Rakow, R | 1 |
| Shelton-Repella, J | 1 |
| Post, R | 1 |
| Weinberger, DR | 2 |
| Dienes, K | 1 |
| Barnea-Goraly, N | 1 |
| Ketter, T | 1 |
| Nudmamud, S | 1 |
| Davanzo, P | 3 |
| Yue, K | 3 |
| Belin, T | 2 |
| Mintz, J | 2 |
| Venkatraman, TN | 1 |
| Santoro, E | 1 |
| Barnett, S | 1 |
| McCracken, J | 2 |
| Sellars, MC | 1 |
| Wood, SJ | 1 |
| Berger, G | 1 |
| Velakoulis, D | 1 |
| Phillips, LJ | 1 |
| McGorry, PD | 1 |
| Yung, AR | 1 |
| Desmond, P | 1 |
| Pantelis, C | 1 |
| Blasi, G | 1 |
| Brudaglio, F | 1 |
| Sciota, D | 1 |
| Altamura, M | 1 |
| Antonucci, N | 1 |
| Scarabino, T | 1 |
| Nardini, M | 1 |
| Frey, BN | 3 |
| Folgierini, M | 1 |
| Brambilla, P | 2 |
| Sassi, RB | 2 |
| Mallinger, AG | 1 |
| Frank, E | 1 |
| Kupfer, D | 1 |
| Keshavan, MS | 2 |
| Axelson, D | 1 |
| Ramos, RT | 1 |
| Ryan, N | 1 |
| Birmaher, B | 1 |
| Daniels, JP | 1 |
| Gallelli, KA | 1 |
| Wagner, CM | 1 |
| Karchemskiy, A | 1 |
| Yildiz-Yesiloglu, A | 1 |
| Ankerst, DP | 1 |
| Atmaca, M | 1 |
| Yildirim, H | 1 |
| Ozdemir, H | 1 |
| Poyraz, AK | 1 |
| Tezcan, E | 1 |
| Ogur, E | 1 |
| Tsai, GE | 1 |
| Huggins, T | 1 |
| Coyle, JT | 1 |
| Post, RM | 1 |
| Amaral, JA | 1 |
| Tamada, RS | 1 |
| Issler, CK | 1 |
| Cerri, GG | 1 |
| de Castro, CC | 1 |
| Frangou, S | 1 |
| Lewis, M | 1 |
| Wollard, J | 1 |
| Simmons, A | 1 |
| Bryan, HS | 1 |
| Stanford, KE | 2 |
| Bhagwagar, Z | 1 |
| Wylezinska, M | 1 |
| Jezzard, P | 1 |
| Evans, J | 1 |
| Ashworth, F | 1 |
| Sule, A | 1 |
| Matthews, PM | 1 |
| Myint, AM | 1 |
| Kim, YK | 1 |
| Verkerk, R | 1 |
| Park, SH | 1 |
| Scharpé, S | 1 |
| Steinbusch, HW | 1 |
| Leonard, BE | 1 |
| Binesh, N | 1 |
| Ventura, J | 1 |
| O'Neill, J | 1 |
| Guze, B | 1 |
| Curran, JG | 1 |
| Ortiz, O | 1 |
| Malhi, GS | 1 |
| Ivanovski, B | 1 |
| Wen, W | 1 |
| Moss, K | 1 |
| Sachdev, P | 1 |
| Walss-Bass, C | 1 |
| Matsuo, K | 1 |
| Bowden, CL | 1 |
| Escamilla, MA | 1 |
| Molina, V | 2 |
| Sánchez, J | 1 |
| Sanz, J | 1 |
| Reig, S | 1 |
| Benito, C | 1 |
| Leal, I | 2 |
| Sarramea, F | 1 |
| Rebolledo, R | 1 |
| Palomo, T | 1 |
| Desco, M | 1 |
| Kraft, S | 1 |
| Unal, SS | 1 |
| Mrazek, DA | 1 |
| Marcus, SM | 1 |
| Lan, MJ | 1 |
| McLoughlin, GA | 1 |
| Griffin, JL | 1 |
| Tsang, TM | 1 |
| Huang, JT | 1 |
| Yuan, P | 1 |
| Manji, H | 1 |
| Holmes, E | 1 |
| Bahn, S | 1 |
| Colla, M | 1 |
| Bubner, M | 1 |
| Heidenreich, JO | 1 |
| Bajbouj, M | 1 |
| Seifert, F | 1 |
| Luborzewski, A | 1 |
| Heuser, I | 1 |
| Kronenberg, G | 1 |
| Sarramea Crespo, F | 1 |
| Luque, R | 1 |
| Prieto, D | 1 |
| Sau, P | 1 |
| Albert, C | 1 |
| de Luxan, A | 1 |
| Osuna, MI | 1 |
| Ruiz, M | 1 |
| Galán, R | 1 |
| Cabaleiro, F | 1 |
| Kloos, A | 1 |
| Weller, EB | 1 |
| Weller, RA | 1 |
| Daunderer, M | 1 |
| Hamakawa, H | 1 |
| Kato, T | 1 |
| Murashita, J | 1 |
| Kato, N | 1 |
| Ohara, K | 2 |
| Isoda, H | 1 |
| Suzuki, Y | 1 |
| Takehara, Y | 1 |
| Ochiai, M | 1 |
| Takeda, H | 1 |
| Igarashi, Y | 1 |
| Winsberg, ME | 1 |
| Sachs, N | 1 |
| Tate, DL | 1 |
| Adalsteinsson, E | 1 |
| Ketter, TA | 1 |
| Castillo, M | 1 |
| Kwock, L | 1 |
| Courvoisie, H | 1 |
| Hooper, SR | 1 |
| Moore, GJ | 2 |
| Bebchuk, JM | 2 |
| Hasanat, K | 1 |
| Seraji-Bozorgzad, N | 1 |
| Wilds, IB | 2 |
| Faulk, MW | 1 |
| Koch, S | 1 |
| Glitz, DA | 1 |
| Jolkovsky, L | 1 |
| Manji, HK | 2 |
| Menji, HK | 1 |
| Oshiro, T | 1 |
| Strober, M | 1 |
| Eliaz, Y | 1 |
| Schuff, N | 1 |
| Sharma, R | 1 |
| Venkatasubramanian, PN | 1 |
| Bárány, M | 1 |
| Davis, JM | 1 |
| Stoll, AL | 1 |
| Guimaraes, AR | 1 |
| Miller, C | 1 |
| Gonzalez, RG | 1 |
| Müller-Oerlinghausen, B | 1 |
| Imiela, M | 1 |
| Rees, JR | 1 |
| Allsopp, MN | 1 |
| Hullin, RP | 1 |
| Consbruch, U | 1 |
| Orth, M | 1 |
| Degkwitz, R | 1 |
| Jenner, FA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Pilot Study of Glycine Augmentation in Carriers of a Mutation in the Gene Encoding Glycine Decarboxylase[NCT01720316] | Phase 2 | 2 participants (Actual) | Interventional | 2012-12-10 | Completed | ||
| Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine[NCT02304432] | Early Phase 1 | 2 participants (Actual) | Interventional | 2015-09-27 | Completed | ||
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| [NCT00181636] | 25 participants | Interventional | Completed | ||||
| An Investigation Examining the Evidence for Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder[NCT00327756] | Phase 2 | 0 participants (Actual) | Interventional | 2006-05-31 | Withdrawn | ||
| Targeted Alterations in n-3 and n-6 Fatty Acids for the Management of Mood Variability in the Maintenance Phase of Bipolar Disorder[NCT02272010] | 83 participants (Actual) | Interventional | 2014-10-31 | Completed | |||
| Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes: Role of Inflammation, Kynurenine Pathway, and Structural and Functional Brain Connectivity as Biomarkers[NCT03580967] | Phase 4 | 0 participants (Actual) | Interventional | 2019-07-01 | Withdrawn (stopped due to COVID-19 Pandemic interfered with Pt recruitment) | ||
| Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients[NCT00870311] | Phase 4 | 28 participants (Actual) | Interventional | 1996-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
Auditory evoked potentials amplitude: P50 ratio (S2/S1). Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | ratio (Number) |
|---|---|
| Auditory ERPs Amplitude (Deg) Baseline: Subject 2 | 44.51 |
| Auditory ERPs Amplitude (Deg) 6 Weeks of Glycine: Subject 2 | 35.67 |
Auditory evoked potentials amplitude: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz; P50 S1 and S2 amplitude; mismatch negativity (MMN) at fz and cz. Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | microvolts (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| P300 amplitude at fz | P300 amplitude at cz | P300 amplitude at pz | N100 amplitude at fz | N100 amplitude at cz | P200 amplitude at fz | P200 amplitude at cz | P50 S1 amplitude | P50 S2 amplitude | MMN amplitude at fz | MMN amplitude at cz | |
| Auditory ERPs Amplitude (Deg) 6 Weeks of Glycine: Subject 2 | 3.74 | 6.6 | 5.57 | -4.71 | -3.89 | 6.29 | 7.8 | 2.2 | 0.78 | -1.004 | -1.322 |
| Auditory ERPs Amplitude (Deg) Baseline: Subject 2 | -0.635 | 6.53 | 5.34 | -3.93 | -3.62 | 1.662 | 6.59 | 2.76 | 1.23 | -3.356 | -4.13 |
Auditory evoked potentials gamma: G40 hz phase locking at fz and cz; G20 hz phase locking response at fz and cz G30 hz phase locking response at fz and cz. Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | microvolts squared (Number) | |||||
|---|---|---|---|---|---|---|
| G40 fz | G40 cz | G20 fz | G20 cz | G30 fz | G30 cz | |
| Auditory ERPs Gamma 6 Weeks of Glycine: Subject 2 | 0.255 | 0.29 | 0.107 | 0.108 | 0.177 | 0.242 |
| Auditory ERPs Gamma Baseline: Subject 2 | 0.135 | 0.168 | 0.023 | 0.03 | 0.19 | 0.163 |
Auditory evoked potentials latency: P300 at fz, cz, and pz); N100 at fz and cz); P200 at fz and cz. Participants were assessed at baseline and in week of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | msec (Number) | ||||||
|---|---|---|---|---|---|---|---|
| P300 latency at fz | P300 latency at cz | P300 latency at pz | N100 latency at fz | N100 latency at cz | P200 latency at fz | P200 latency at cz | |
| Auditory ERPs Latency (ms) 6 Weeks of Glycine: Subject 2 | 300.78 | 293 | 294.92 | 94 | 94 | 205 | 203 |
| Auditory ERPs Latency (ms) Baseline: Subject 2 | 279.3 | 279.3 | 279.3 | 97.66 | 91.8 | 197.27 | 193.4 |
Magnetic resonance spectroscopy GABA/Cr. Participants were assessed 1) pre-glycine treatment (baseline) and 2) in week 6 of open-label glycine treatment measured in posterior occipital cortex. (NCT01720316)
Timeframe: Baseline and week 6 of glycine
| Intervention | ratio (Number) | |
|---|---|---|
| Baseline GABA/Cr | Week 6 of glycine tx GABA/Cr | |
| Subject1: Brain GABA/CR Ratio- Baseline/Week 6 of Glycine | 0.16 | 0.22 |
| Subject2: Brain GABA/CR Ratio- Baseline/Week 6 of Glycine | 0.27 | 0.24 |
magnetic resonance spectroscopy - glutamate metabolite level. Participants were assessed 1) pre-glycine treatment and in week 6 of open-label glycine treatment. Measured in posterior occipital cortex. (NCT01720316)
Timeframe: baseline and week 6 of glycine
| Intervention | ratio (Number) | |
|---|---|---|
| Baseline brain glutamate/Cr ratio | Week 6 brain glutamate/Cr ratio | |
| Subject1: Brain Glutamate/CR Ratio- Baseline/Week 6 of Glycine | 0.98 | 0.84 |
| Subject2: Brain Glutamate/CR Ratio- Baseline/Week 6 of Glycine | 2.053 | 1.13 |
magnetic resonance spectroscopy: glycine/creatine ratio. Participants were assessed at 1) BASELINE PRE-GLYCINE TREATMENT: pre-glycine challenge drink, 60 minutes post challenge drink, 80 minutes post challenge drink, 100 minutes post challenge drink, and 120 minutes post challenge drink (0.4 g/kg up to max of 30 g); and 2) IN WEEK 6 OF OPEN-LABEL GLYCINE TREATMENT: pre-glycine dose, and 60 minutes, 80 minutes, 100 minutes and 120 minutes post daily dose of glycine. Measured in posterior occipital cortex (NCT01720316)
Timeframe: baseline (pre-challenge, 60, 80, 100, 120 minutes post-challenge), and week 6 of glycine (pre-dose and 60, 80, 100, 120 minutes post-dose
| Intervention | ratio (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline - pre-challenge drink | Baseline 60 minutes post challenge drink | Baseline 80 minutes post challenge drink | Baseline 100 minutes post challenge drink | Baseline 120 minutes post challenge drink | Week 6 of glycine - pre-glycine dose | Week 6 of glycine - 60 minutes post glycine dose | Week 6 of glycine - 80 minutes post glycine dose | Week 6 of glycine - 100 minutes post glycine dose | Week 6 of glycine - 120 minutes post glycine dose | |
| Subject 2:Brain Glycine/CR Ratio at Baseline/Week 6 of Glycine | 0.5691 | 0.3918 | 0.6428 | 0.6363 | 0.9559 | 0.3235 | 0.3807 | 0.5591 | 0.4142 | 0.3545 |
| Subject1: Brain Glycine/CR Ratio at Baseline/Week 6 of Glycine | 0.2558 | 0.6157 | 0.6631 | 0.5938 | 0.6953 | 0.6573 | 0.2983 | 0.4577 | 0.5751 | 0.3842 |
Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within and after each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BPRS at baseline | BPRS at 2 weeks intervention 1 | BPRS at 4 weeks intervention 1 | BPRS at 6 weeks intervention 1 | BPRS, end of washout1 | BPRS at 2 weeks intervention 2 | BPRS at 4 weeks intervention 2 | BPRS at 6 weeks intervention 2 | BPRS, end of washout2 | BPRS at 2 weeks open label | BPRS at 4 weeks open label | BPRS at 6 weeks open label | BPRS, end of washout3 | |
| Glycine, Then Placebo | 39 | 38 | 32 | 21 | 22 | 37 | 31 | 37 | 32 | 23 | 22 | 21 | 19 |
| Placebo, Then Glycine | 46 | 38 | 39 | 28 | 34 | 32 | 20 | 23 | 24 | 20 | 18 | 19 | 23 |
Clinical Global Impression (CGI) severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT01720316)
Timeframe: CGI at baseline and at 2 weeks, 4 weeks, and 6 weeks per treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI severity score at baseline | CGI severity score at 2 weeks intervention 1 | CGI severity score at 4 weeks intervention 1 | CGI severity score at 6 weeks intervention 1 | CGI severity score, end of washout1 | CGI severity score at 2 weeks intervention 2 | CGI severity score at 4 weeks intervention 2 | CGI severity score at 6 weeks intervention 2 | CGI severity score, end of washout2 | CGI severity score at 2 weeks open label | CGI severity score at 4 weeks open label | CGI severity score at 6 weeks open label | CGI severity score, end of washout3 | |
| Glycine, Then Placebo | 4 | 4 | 3 | 2 | 2 | 4 | 4 | 4 | 4 | 3 | 3 | 2 | 2 |
| Placebo, Then Glycine | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 2 | 2 |
Clinical Global Impression (CGI) therapeutic effect scores measure degree of improvement as marked (1), moderate (5), minimal (9) or unchanged/worse (13). (NCT01720316)
Timeframe: at 2 weeks, 4 weeks, and 6 weeks within each treatment period
| Intervention | score (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI therapeutic effect at 2 weeks intervention 1 | CGI therapeutic effect at 4 weeks intervention 1 | CGI therapeutic effect at 6 weeks intervention 1 | CGI therapeutic effect, end of washout1 | CGI therapeutic effect at 2 weeks intervention 2 | CGI therapeutic effect at 4 weeks intervention 2 | CGI therapeutic effect at 6 weeks intervention 2 | CGI therapeutic effect, end of washout2 | CGI therapeutic effect at 2 weeks open label | CGI therapeutic effect at 4 weeks open label | CGI therapeutic effect at 6 weeks open label | CGI therapeutic effect, end of washout3 | |
| Glycine, Then Placebo | 13 | 5 | 5 | 5 | 13 | 13 | 13 | 13 | 5 | 5 | 1 | 1 |
| Placebo, Then Glycine | 5 | 5 | 5 | 5 | 13 | 5 | 5 | 5 | 1 | 1 | 1 | 1 |
Hamilton Depression Scale measures severity of depression symptoms. The sum of ratings for 9 depression symptoms are measured on a scale from 0-2 with 0 meaning no symptoms and 2 meaning some level of severity of that specific symptom. The rating for 1 depression symptom is measured on a scale from 0-3 with 0 meaning no symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms are measured on a scale from 0-4 with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depression symptoms at baseline | Depression symptoms at 2 weeks intervention 1 | Depression symptoms at 4 weeks intervention 1 | Depression symptoms at 6 weeks intervention 1 | Depression symptoms, end of washout1 | Depression symptoms at 2 weeks intervention 2 | Depression symptoms at 4 weeks intervention 2 | Depression symptoms at 6 weeks intervention 2 | Depression symptoms, end of washout2 | Depression symptoms at 2 weeks open label | Depression symptoms at 4 weeks open label | Depression symptoms at 6 weeks open label | Depression symptoms, end of washout3 | |
| Glycine, Then Placebo | 18 | 17 | 11 | 3 | 1 | 19 | 5 | 7 | 3 | 2 | 2 | 1 | 2 |
| Placebo, Then Glycine | 12 | 5 | 5 | 0 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 0 |
Plasma glycine levels; normal range is 122-467 nM/mL (NCT01720316)
Timeframe: At baseline, during glycine treatment, during placebo treatment and during open-label glycine
| Intervention | nM/mL (Number) | |||
|---|---|---|---|---|
| Baseline | Glycine double-blind | Placebo | Glycine open-label | |
| Glycine Then Placebo | 216 | 410 | 194 | 516 |
| Placebo Then Glycine | 271 | 761 | 347 | 634 |
Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of ratings for 7 symptoms of mania is measured on a scale from 0-4 and the sum of 4 symptoms of mania is measured on a scale from 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Manic symptoms at baseline | Manic symptoms at 2 weeks intervention 1 | Manic symptoms at 4 weeks intervention 1 | Manic symptoms at 6 weeks intervention 1 | Manic symptoms, end of washout1 | Manic symptoms at 2 weeks intervention 2 | Manic symptoms at 4 weeks intervention 2 | Manic symptoms at 6 weeks intervention 2 | Manic symptoms, end of washout2 | Manic symptoms at 2 weeks open label | Manic symptoms at 4 weeks open label | Manic symptoms at 6 weeks open label | Manic symptoms, end of washout3 | |
| Glycine, Then Placebo | 4 | 1 | 0 | 0 | 0 | 17 | 0 | 2 | 2 | 1 | 0 | 0 | 0 |
| Placebo, Then Glycine | 7 | 7 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Scores on each of 8 domains of cognitive function (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem solving, social cognition, overall composite). Scores are T scores ranging from 0-100, with 50 representing the mean for a population based on a normal distribution; standard deviation of 10. Only overall composite score is entered. (NCT01720316)
Timeframe: At baseline, during glycine treatment, during placebo treatment and during open-label glycine
| Intervention | units on a scale (Number) | |
|---|---|---|
| Participant 1 | Participant 2 | |
| Baseline | 45 | 48 |
| Composite Score on Glycine, Double-blind | 52 | 52 |
| Composite Score on Glycine, Open-label | 49 | 46 |
| Composite Score on Placebo | 52 | 55 |
Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms are measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period and after each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Positive symptoms at baseline | Positive symptoms at 2 weeks intervention 1 | Positive symptoms at 4 weeks intervention 1 | Positive symptoms at 6 weeks intervention 1 | Positive symptoms, end of washout1 | Positive symptoms at 2 weeks intervention 2 | Positive symptoms at 4 weeks intervention 2 | Positive symptoms at 6 weeks intervention 2 | Positive symptoms, end of washout2 | Positive symptoms at 2 weeks open label | Positive symptoms at 4 weeks open label | Positive symptoms at 6 weeks open label | Positive symptoms, end of washout3 | |
| Glycine, Then Placebo | 13 | 12 | 9 | 8 | 7 | 12 | 11 | 14 | 14 | 9 | 9 | 7 | 7 |
| Placebo, Then Glycine | 19 | 20 | 19 | 13 | 13 | 12 | 10 | 11 | 11 | 8 | 7 | 8 | 8 |
Auditory evoked potential amplitude: P50 ratio (P50 S2/S1) (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | ratio (Number) | |
|---|---|---|
| P50 ratio: Baseline | P50 ratio: Week 8 of DCS | |
| First Open Label DCS | 44.51 | 30 |
Auditory evoked potential amplitude: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz; P50 S1 and S2; mismatch negativity (MMN) at fz and cz. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | microvolts (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P300 at fz: Baseline | P300 at cz: Baseline | P300 at pz: Baseline | N100 at fz: Baseline | N100 at cz: Baseline | P200 at fz: Baseline | P200 at cz: Baseline | P50 S1: Baseline | P50 S2: Baseline | MMN at fz: Baseline | MMN at cz: Baseline | P300 at fz: Week 8 of DCS | P300 at cz: Week 8 of DCS | P300 at pz: Week 8 of DCS | N100 at fz: Week 8 of DCS | N100 at cz: Week 8 of DCS | P200 at fz: Week 8 of DCS | P200 at cz: Week 8 of DCS | P50 S1: Week 8 of DCS | P50 S2: Week 8 of DCS | MMN at fz: Week 8 of DCS | MMN at cz: Week 8 of DCS | |
| First Open Label DCS | -0.635 | 6.529 | 5.340 | -3.926 | -3.615 | 1.662 | 6.591 | 2.759 | 1.23 | -3.356 | -4.130 | 3.030 | 6.810 | 6.620 | -3.260 | -3.940 | 8.200 | 8.160 | 1.36 | 0.4 | -3.330 | -1.540 |
Auditory evoked potential gamma: G40 hz phase locking at fz and cz; G30 hz phase locking at fz and cz; G20 hz phase locking at fz and cz (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | microvolts squared (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| G40 hz phase locking at fz: Baseline | G40 hz phase locking at cz: Baseline | G30 hz phase locking at fz: Baseline | G30 hz phase locking at cz: Baseline | G20 hz phase locking at fz: Baseline | G20 hz phase locking at cz: Baseline | G40 hz phase locking at fz: Week 8 of DCS | G40 hz phase locking at cz: Week 8 of DCS | G30 hz phase locking at fz: Week 8 of DCS | G30 hz phase locking at cz: Week 8 of DCS | G20 hz phase locking at fz: Week 8 of DCS | G20 hz phase locking at cz: Week 8 of DCS | |
| First Open Label DCS | 0.135 | 0.168 | 0.190 | 0.163 | 0.023 | 0.030 | 0.344 | 0.381 | 0.168 | 0.19 | 0.01 | -0.01 |
Auditory evoked potential latency: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | msec (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P300 at fz: Baseline | P300 at cz: Baseline | P300 at pz: Baseline | N100 at fz: Baseline | N100 at cz: Baseline | P200 at fz: Baseline | P200 at cz: Baseline | P300 at fz: Week 8 of DCS | P300 at cz: Week 8 of DCS | P300 at pz: Week 8 of DCS | N100 at fz: Week 8 of DCS | N100 at cz: Week 8 of DCS | P200 at fz: Week 8 of DCS | P200 at cz: Week 8 of DCS | |
| First Open Label DCS | 279.297 | 279.297 | 279.297 | 97.656 | 91.797 | 197.266 | 193.359 | 294.920 | 294.000 | 294 | 87.9 | 88.000 | 212.890 | 212.000 |
Proton magnetic resonance spectroscopy at 4T: brain glycine/CR ratio. Participants were assessed at baseline (pre-glycine challenge dose and 60, 80, 100 and 120 minutes post glycine dose) and in week 8 of of open-label DCS treatment: pre-DCS dose, and 60, 80, 100 and 120 minutes post DCS dose. Measured in posterior occipital cortex. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | ratio (Median) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Baseline at 60 minutes | Baseline at 80 minutes | Baseline at 100 minutes | Baseline at 120 minutes | Week 8 of DCS: Baseline | Week 8 of DCS: 60 minutes | Week 8 of DCS: 80 minutes | Week 8 of DCS: 100 minutes | Week 8 of DCS: 120 minutes | |
| Open Label DCS | 0.41245 | 0.50375 | 0.65295 | 0.61505 | 0.8256 | 0.10977 | 0.248885 | 0.32609 | 0.32052 | 0.312155 |
Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline BPRS | 2 weeks BPRS | 4 weeks BPRS | 6 weeks BPRS | 8 weeks BPRS | 10 weeks BPRS | 12 weeks BPRS | 14 weeks BPRS | 16 weeks BPRS | 18 weeks BPRS | 20 weeks BPRS | 22 weeks BPRS | 24 weeks BPRS | |
| First Open Label DCS | 37 | 25 | 26 | 24 | 24.5 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 31.5 | 30.5 | 28 | 25.5 | 26 | 26.5 | 26 | 25.5 | 28.5 | 27 | 25 | 24.5 | 26.5 |
Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline BPRS for first intervention | 2 weeks BPRS for first intervention | 4 weeks BPRS for first intervention | 6 weeks BPRS for first intervention | Baseline BPRS for second intervention | 2 weeks BPRS for second intervention | 4 weeks BPRS for second intervention | 6 weeks BPRS for second intervention | |
| DCS First, Then Placebo | 26 | 25 | 25 | 26 | 39 | 45 | 45 | 38 |
| Placebo First, Then DCS | 29 | 35 | 33 | 35 | 36 | 30 | 27 | 28 |
CGI severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline CGI | 2 weeks CGI | 4 weeks CGI | 6 weeks CGI | 8 weeks CGI | 10 weeks CGI | 12 weeks CGI | 14 weeks CGI | 16 weeks CGI | 18 weeks CGI | 20 weeks CGI | 22 weeks CGI | 24 weeks CGI | |
| First Open Label DCS | 4 | 2 | 2 | 2 | 2 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 3 | 2.5 | 2 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
CGI severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline CGI for first intervention | 2 weeks CGI for first intervention | 4 weeks CGI for first intervention | 6 weeks CGI for first intervention | Baseline CGI for second intervention | 2 weeks CGI for second intervention | 4 weeks CGI for second intervention | 6 weeks CGI for second intervention | |
| DCS First, Then Placebo | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 |
| Placebo First, Then DCS | 1 | 3 | 3 | 3 | 3 | 2 | 2 | 2 |
Hamilton Depression Scale (HAM) measures severity of depression symptoms. The sum of the ratings for 9 depression symptoms is measured on a scale of 0-2 with 0 meaning no depression symptoms and 2 meaning some level of severity of that specific symptom. The rating for one depression symptom is measured on a scale of 0-3 with 0 meaning no depression symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms is measured on a scale of 0-4, with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. Higher scores indicate worse depression symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline HAM | 2 weeks HAM | 4 weeks HAM | 6 weeks HAM | 8 weeks HAM | 10 weeks HAM | 12 weeks HAM | 14 weeks HAM | 16 weeks HAM | 18 weeks HAM | 20 weeks HAM | 22 weeks HAM | 24 weeks HAM | |
| First Open Label DCS | 5 | 1.5 | 1 | 0.5 | 1.5 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 0.5 | 1 | 1 | 0 | 2.5 | 0 | 0 | 0 | 3.5 | 0 | 0 | 0 | 0 |
Hamilton Depression Scale (HAM) measures severity of depression symptoms. The sum of the ratings for 9 depression symptoms is measured on a scale of 0-2 with 0 meaning no depression symptoms and 2 meaning some level of severity of that specific symptom. The rating for one depression symptom is measured on a scale of 0-3 with 0 meaning no depression symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms is measured on a scale of 0-4, with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. Higher scores indicate worse depression symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline HAM for first intervention | 2 weeks HAM for first intervention | 4 weeks HAM for first intervention | 6 weeks HAM for first intervention | Baseline HAM for second intervention | 2 weeks HAM for second intervention | 4 weeks HAM for second intervention | 6 weeks HAM for second intervention | |
| DCS First, Then Placebo | 0 | 1 | 0 | 0 | 2 | 12 | 9 | 2 |
| Placebo First, Then DCS | 4 | 5 | 2 | 10 | 0 | 0 | 0 | 0 |
Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of the ratings for 7 symptoms of mania is measured on a scale of 0-4 and the sumof 4 symptoms of mania is measured on a scale of 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline YMRS | 2 weeks YMRS | 4 weeks YMRS | 6 weeks YMRS | 8 weeks YMRS | 10 weeks YMRS | 12 weeks YMRS | 14 weeks YMRS | 16 weeks YMRS | 18 weeks YMRS | 20 weeks YMRS | 22 weeks YMRS | 24 weeks YMRS | |
| First Open Label DCS | 2 | 1 | 1 | 0 | 0 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of the ratings for 7 symptoms of mania is measured on a scale of 0-4 and the sumof 4 symptoms of mania is measured on a scale of 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline YMRS for first intervention | 2 weeks YMRS for first intervention | 4 weeks YMRS for first intervention | 6 weeks YMRS for first intervention | Baseline YMRS for second intervention | 2 weeks YMRS for second intervention | 4 weeks YMRS for second intervention | 6 weeks YMRS for second intervention | |
| DCS First, Then Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo First, Then DCS | 1 | 0 | 0 | 0 | 4 | 1 | 1 | 1 |
Scores on each of 8 domains of cognitive function (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem solving, social cognition, overall composite). Scores are T scores ranging from 0-100, with 50 representing the mean for a population based on a normal distribution, standard deviation of 10. Higher scores signify better functioning. (NCT02304432)
Timeframe: Baseline and Week 8 of open-label DCS treatment
| Intervention | T scores (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Processing Speed | Baseline Attention/Vigilance | Baseline Working Memory | Baseline Verbal Learning | Baseline Visual Learning | Baseline Reasoning/Problem Solving | Baseline Social Cognition | Baseline Overall Composite Score | Week 8 of open-label DCS Processing Speed | Week 8 of open-label DCS Attention/Vigilance | Week 8 of open-label DCS Working Memory | Week 8 of open-label DCS Verbal Learning | Week 8 of open-label DCS Visual Learning | Week 8 of open-label DCS Reasoning/Problem Solving | Week 8 of open-label DCS Social Cognition | Week 8 of open-label DCS Overall Composite Score | |
| Open Label DCS | 48.5 | 44.5 | 38.5 | 54 | 50.5 | 52.5 | 48 | 46.5 | 52.5 | 47.5 | 50.5 | 43.5 | 54.5 | 66.5 | 44.5 | 51.5 |
Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms.The sum of ratings for seven negative symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline positive | Baseline negative | 2 weeks positive | 2 weeks negative | 4 weeks positive | 4 weeks negative | 6 weeks positive | 6 weeks negative | 8 weeks positive | 8 weeks negative | 10 weeks positive | 10 weeks negative | 12 weeks positive | 12 weeks negative | 14 weeks positive | 14 weeks negative | 16 weeks positive | 16 weeks negative | 18 weeks positive | 18 weeks negative | 20 weeks positive | 20 weeks negative | 22 weeks positive | 22 weeks negative | 24 weeks positive | 24 weeks negative | |
| First Open Label DCS | 14.5 | 14.5 | 10 | 12 | 10.5 | 12 | 9 | 12 | 9 | 12 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 11 | 14 | 11 | 14 | 10.5 | 13.5 | 9 | 13 | 9.5 | 12 | 10.5 | 13 | 11 | 12 | 10 | 12 | 10.5 | 12 | 10.5 | 12 | 10.5 | 12 | 9.5 | 12 | 10 | 12 |
Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms.The sum of ratings for seven negative symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline positive for first intervention | Baseline negative symptoms for first intervention | 2 weeks positive for first intervention | 2 weeks negative for first intervention | 4 weeks positive for first intervention | 4 weeks negative for first intervention | 6 weeks positive for first intervention | 6 weeks negative for first intervention | Baseline positive for second intervention | Baseline negative for second intervention | 2 weeks positive for second intervention | 2 weeks negative for second intervention | 4 weeks positive for second intervention | 4 weeks negative for second intervention | 6 weeks positive for second intervention | 6 weeks negative for second intervention | |
| DCS First, Then Placebo | 10 | 15 | 10 | 15 | 10 | 15 | 10 | 15 | 15 | 18 | 15 | 18 | 15 | 18 | 14 | 18 |
| Placebo First, Then DCS | 11 | 9 | 12 | 15 | 11 | 13 | 13 | 13 | 13 | 13 | 10 | 11 | 9 | 11 | 9 | 11 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
6 reviews available for aspartic acid and Bipolar Disorder
| Article | Year |
|---|---|
Glutamatergic and N-Acetylaspartate Metabolites in Bipolar Disorder: A Systematic Review and Meta-Analysis of Proton Magnetic Resonance Spectroscopy Studies.
Topics: Aspartic Acid; Bipolar Disorder; Depressive Disorder, Major; Glutamic Acid; Glutamine; Humans; Proto | 2022 |
Proton magnetic resonance spectroscopy changes after lithium treatment. Systematic review.
Topics: Antimanic Agents; Aspartic Acid; Bipolar Disorder; Brain; Choline; Cross-Sectional Studies; gamma-Am | 2018 |
Metabolomics in patients with psychosis: A systematic review.
Topics: 3-Hydroxybutyric Acid; Aspartic Acid; Biomarkers; Bipolar Disorder; Creatine; Female; Glutamic Acid; | 2018 |
Applications for magnetic resonance imaging in bipolar disorder.
Topics: Antipsychotic Agents; Aspartic Acid; Bipolar Disorder; Brain; gamma-Aminobutyric Acid; Glutamic Acid | 2007 |
Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Brain Chemistry; Child; Choline; Creatine; Glutamic Acid; Gl | 2006 |
Biologic basis of bipolar disorder in children and adolescents.
Topics: Adolescent; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Brain; Brain-Derived Neurotrophic Fac | 2008 |
16 trials available for aspartic acid and Bipolar Disorder
| Article | Year |
|---|---|
Effects of infliximab on brain neurochemistry of adults with bipolar depression.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Brain; Glutamic Acid; Humans; Infliximab; Neurochemistry; Pr | 2021 |
A Magnetic Resonance Spectroscopy Study of Lovastatin for Treating Bipolar Mood Disorder: A 4-Week Randomized Double-Blind, Placebo- Controlled Clinical Trial.
Topics: Adolescent; Adult; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Brain; Choline; Creatine; Doub | 2017 |
Brain lithium, N-acetyl aspartate and myo-inositol levels in older adults with bipolar disorder treated with lithium: a lithium-7 and proton magnetic resonance spectroscopy study.
Topics: Aged; Aged, 80 and over; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Brain; Cross-Sectional S | 2008 |
Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation.
Topics: Adolescent; Antimanic Agents; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Bipolar | 2009 |
Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Bipolar Disorder; Brain Mapping; Choline; Cholinesterase Inh | 2009 |
Neurometabolite effects of response to quetiapine and placebo in adolescents with bipolar depression.
Topics: Adolescent; Antipsychotic Agents; Aspartic Acid; Bipolar Disorder; Child; Dibenzothiazepines; Female | 2012 |
Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Cerebral Cortex; Ch | 2003 |
Decreased N-acetylaspartate in children with familial bipolar disorder.
Topics: Adolescent; Aspartic Acid; Bipolar Disorder; Child; Creatine; Family Health; Female; Humans; Magneti | 2003 |
Proton magnetic resonance spectroscopy of the frontal lobe and cerebellar vermis in children with a mood disorder and a familial risk for bipolar disorders.
Topics: Aspartic Acid; Bipolar Disorder; Brain Chemistry; Cerebellum; Child; Family; Female; Frontal Lobe; H | 2003 |
Neurochemical effects of olanzapine in first-hospitalization manic adolescents: a proton magnetic resonance spectroscopy study.
Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Aspartic Acid; Benzodiazepines; Bipolar Diso | 2006 |
Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Brain; Double-Blind Method; Eicosapentaenoic Acid; Female; H | 2007 |
Lithium treatment effects on Myo-inositol in adolescents with bipolar depression.
Topics: Adolescent; Antidepressive Agents; Aspartic Acid; Bipolar Disorder; Child; Female; Humans; Inositol; | 2006 |
Proton magnetic resonance spectroscopy in youth with severe mood dysregulation.
Topics: Antimanic Agents; Arousal; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Bipolar Dis | 2008 |
Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?
Topics: Adult; Analysis of Variance; Aspartic Acid; Bipolar Disorder; Brain; Double-Blind Method; Female; Ge | 2000 |
Lithium-induced increase in human brain grey matter.
Topics: Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Brain; Female; Humans; Lithium; Magnetic Resonan | 2000 |
Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder.
Topics: Adolescent; Area Under Curve; Aspartic Acid; Bipolar Disorder; Child; Creatine; Demography; Drug Adm | 2001 |
91 other studies available for aspartic acid and Bipolar Disorder
| Article | Year |
|---|---|
Metabolic abnormalities in the basal ganglia and cerebellum in bipolar disorder: A multi-modal MR study.
Topics: Aspartic Acid; Basal Ganglia; Bipolar Disorder; Cerebellum; Creatine; Cross-Sectional Studies; Human | 2022 |
Elevated choline in dorsolateral prefrontal cortex of lithium responders with bipolar I disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Dorsolateral Prefrontal Cortex; Humans; L | 2023 |
Elevated choline in dorsolateral prefrontal cortex of lithium responders with bipolar I disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Dorsolateral Prefrontal Cortex; Humans; L | 2023 |
Elevated choline in dorsolateral prefrontal cortex of lithium responders with bipolar I disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Dorsolateral Prefrontal Cortex; Humans; L | 2023 |
Elevated choline in dorsolateral prefrontal cortex of lithium responders with bipolar I disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Dorsolateral Prefrontal Cortex; Humans; L | 2023 |
Elevated choline in dorsolateral prefrontal cortex of lithium responders with bipolar I disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Dorsolateral Prefrontal Cortex; Humans; L | 2023 |
Elevated choline in dorsolateral prefrontal cortex of lithium responders with bipolar I disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Dorsolateral Prefrontal Cortex; Humans; L | 2023 |
Elevated choline in dorsolateral prefrontal cortex of lithium responders with bipolar I disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Dorsolateral Prefrontal Cortex; Humans; L | 2023 |
Elevated choline in dorsolateral prefrontal cortex of lithium responders with bipolar I disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Dorsolateral Prefrontal Cortex; Humans; L | 2023 |
Elevated choline in dorsolateral prefrontal cortex of lithium responders with bipolar I disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Dorsolateral Prefrontal Cortex; Humans; L | 2023 |
Altered biochemical metabolism and its lateralization in the cortico-striato-cerebellar circuit of unmedicated bipolar II depression.
Topics: Adult; Aspartic Acid; Basal Ganglia; Bipolar Disorder; Cerebellum; Choline; Creatine; Cross-Sectiona | 2019 |
Neurometabolic alterations in bipolar disorder with anxiety symptoms: A proton magnetic resonance spectroscopy study of the prefrontal whiter matter.
Topics: Anxiety; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Humans; Proton Magnetic Resonance Spect | 2021 |
Anterior cingulate cortex neuro-metabolic changes underlying lithium-induced euthymia in bipolar depression: A longitudinal
Topics: Aspartic Acid; Bipolar Disorder; Brain; Choline; Creatine; Gyrus Cinguli; Humans; Inositol; Lithium; | 2021 |
Diagnosis and body mass index effects on hippocampal volumes and neurochemistry in bipolar disorder.
Topics: Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Body Mass Index; Brain; Case-Control Studies; Cr | 2017 |
Relationship of executive functioning deficits to N-acetyl aspartate (NAA) and gamma-aminobutyric acid (GABA) in youth with bipolar disorder.
Topics: Adolescent; Aspartic Acid; Bipolar Disorder; Brain; Case-Control Studies; Executive Function; Female | 2018 |
Biochemical abnormalities in basal ganglia and executive dysfunction in acute- and euthymic-episode patients with bipolar disorder: A proton magnetic resonance spectroscopy study.
Topics: Adult; Aspartic Acid; Basal Ganglia; Biomarkers; Bipolar Disorder; Brain; Brain Chemistry; Case-Cont | 2018 |
Lithium-associated anterior cingulate neurometabolic profile in euthymic Bipolar I disorder: A
Topics: Adult; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Brain; Brain Chemistry; Choline; Cyclothym | 2018 |
Associations between executive function impairment and biochemical abnormalities in bipolar disorder with suicidal ideation.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Brain; Case-Control Studies; Cerebral Cortex; Choline; Corpu | 2018 |
Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aspartic Acid; Bipolar Disorder; Case-Control Studies | 2019 |
Lamotrigine Therapy and Biomarkers of Cerebral Energy Metabolism in Older Age Bipolar Depression.
Topics: Aged; Aging; Antipsychotic Agents; Aspartic Acid; Biomarkers; Bipolar Disorder; Cerebral Cortex; Cre | 2019 |
Neurophysiological effects of multiple mood episodes in bipolar disorder.
Topics: Adult; Affect; Amygdala; Aspartic Acid; Attention; Bipolar Disorder; Brain; Brain Mapping; Cerebral | 2019 |
Role of glia in prefrontal white matter abnormalities in first episode psychosis or mania detected by diffusion tensor spectroscopy.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Choline; Creatine; Diffusion Tensor Im | 2019 |
Neurochemical effects of quetiapine in patients with bipolar mania: a proton magnetic resonance spectroscopy study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aspartic Acid; Biomarkers; Bipolar Disorder; Case-Control S | 2013 |
Magnetic resonance spectroscopy imaging of lactate in patients with bipolar disorder.
Topics: Adolescent; Adult; Analysis of Variance; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Female; | 2013 |
Neurochemical abnormalities in unmedicated bipolar depression and mania: a 2D 1H MRS investigation.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Brain; Creatine; Female; Glutamic Acid; Humans; Image Proces | 2013 |
Cortical glutathione levels in young people with bipolar disorder: a pilot study using magnetic resonance spectroscopy.
Topics: Aspartic Acid; Biomarkers; Bipolar Disorder; Case-Control Studies; Female; Functional Neuroimaging; | 2014 |
(1)H-MRS of hippocampus in patients after first manic episode.
Topics: Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Glutamic Acid; Glutamine; Hip | 2014 |
Prospective neurochemical characterization of child offspring of parents with bipolar disorder.
Topics: Adolescent; Analysis of Variance; Aspartic Acid; Bipolar Disorder; Child; Child of Impaired Parents; | 2013 |
Type 2 diabetes mellitus: a potentially modifiable risk factor for neurochemical brain changes in bipolar disorders.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Brain; Creatine; Cross-Sectional Studies; Diabetes Mellitus, | 2015 |
N-acetyl aspartate levels in adolescents with bipolar and/or cannabis use disorders.
Topics: Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Female; Humans; Male; Marijuana Abuse; Prefronta | 2014 |
Similarities of biochemical abnormalities between major depressive disorder and bipolar depression: a proton magnetic resonance spectroscopy study.
Topics: Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Brain; Choline; Creatine; Depressive Disorder, M | 2014 |
Myelin vs axon abnormalities in white matter in bipolar disorder.
Topics: Adult; Aspartic Acid; Axons; Bipolar Disorder; Diffusion Tensor Imaging; Female; Humans; Magnetic Re | 2015 |
Investigation of Heschl's gyrus and planum temporale in patients with schizophrenia and bipolar disorder: a proton magnetic resonance spectroscopy study.
Topics: Adult; Analysis of Variance; Aspartic Acid; Auditory Cortex; Bipolar Disorder; Creatine; Female; Hum | 2015 |
N-acetylaspartate normalization in bipolar depression after lamotrigine treatment.
Topics: Adult; Aged; Aspartic Acid; Biomarkers; Bipolar Disorder; Brain; Dipeptides; Female; Gyrus Cinguli; | 2015 |
Alterations of cerebral glutamate in the euthymic state of patients with bipolar disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; Female; Glutamic Acid; Gyrus Cinguli; Hippocampus; | 2015 |
Hippocampal neurochemical markers in bipolar disorder patients following the first-manic episode: A prospective 12-month proton magnetic resonance spectroscopy study.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Female; Glutamic Acid; Glutamine; Hippocampus; Humans; Male; | 2017 |
Trait-related alterations of N-acetylaspartate in euthymic bipolar patients: A longitudinal proton magnetic resonance spectroscopy study.
Topics: Adult; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Choline; Cyclothymic Disorder; Female; Fro | 2016 |
Main Effects of Diagnoses, Brain Regions, and their Interaction Effects for Cerebral Metabolites in Bipolar and Unipolar Depressive Disorders.
Topics: Adult; Aspartic Acid; Biomarkers; Bipolar Disorder; Case-Control Studies; Choline; Creatine; Depress | 2016 |
Differential neurometabolite alterations in brains of medication-free individuals with bipolar disorder and those with unipolar depression: a two-dimensional proton magnetic resonance spectroscopy study.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Depressive Disorder; Female; Gyrus Cingul | 2016 |
A comparison of neurometabolites between remitted bipolar disorder and depressed bipolar disorder: A proton magnetic resonance spectroscopy study.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Choline; Creatine; Female; Humans; Mal | 2017 |
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Cerebral Co | 2008 |
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Cerebral Co | 2008 |
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Cerebral Co | 2008 |
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Cerebral Co | 2008 |
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Cerebral Co | 2008 |
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Cerebral Co | 2008 |
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Cerebral Co | 2008 |
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Cerebral Co | 2008 |
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Cerebral Co | 2008 |
SNAP-25 genotype influences NAA/Cho in left hippocampus.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; DNA; Female; Genotype; Hippocampus; Humans; Magneti | 2008 |
Neurochemical alterations in adolescent bipolar depression: a proton magnetic resonance spectroscopy pilot study of the prefrontal cortex.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Aspartic Acid; Bipolar Dis | 2008 |
Elevated metabolites within dorsolateral prefrontal cortex in rapid cycling bipolar disorder.
Topics: Adult; Aspartic Acid; Biomarkers; Bipolar Disorder; Brain; Choline; Creatine; Female; Functional Lat | 2009 |
Increased choline-containing compounds in the orbitofrontal cortex and hippocampus in euthymic patients with bipolar disorder: a proton magnetic resonance spectroscopy study.
Topics: Adult; Analysis of Variance; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Choline; Female; | 2009 |
Bipolar disorder comorbid with alcoholism: a 1H magnetic resonance spectroscopy study.
Topics: Adult; Age Factors; Alcoholism; Analysis of Variance; Aspartic Acid; Bipolar Disorder; Brain; Comorb | 2010 |
T2 relaxation time abnormalities in bipolar disorder and schizophrenia.
Topics: Adult; Aspartic Acid; Biomarkers; Bipolar Disorder; Brain; Choline; Creatine; Female; Humans; Magnet | 2010 |
Cortical neurochemistry in euthymic patients with bipolar I disorder.
Topics: Adult; Affect; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Dominance, Cere | 2009 |
Brain glutamatergic characteristics of pediatric offspring of parents with bipolar disorder.
Topics: Adolescent; Analysis of Variance; Aspartic Acid; Bipolar Disorder; Brain Mapping; Child; Child of Im | 2010 |
Differential regional N-acetylaspartate deficits in postmortem brain in schizophrenia, bipolar disorder and major depressive disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Brain; Depressive Disorder, Major; Dipeptides; Female; Human | 2011 |
[Application of lamotrigine in bipolar disorder--3T MR spectroscopy follow up (part 1)].
Topics: Antimanic Agents; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Excitatory Amino Acid Antagoni | 2010 |
Lower N-acetyl-aspartate levels in prefrontal cortices in pediatric bipolar disorder: a ¹H magnetic resonance spectroscopy study.
Topics: Adolescent; Aspartic Acid; Bipolar Disorder; Brain Chemistry; Child; Diagnostic and Statistical Manu | 2011 |
Neurochemical deficits in the cerebellar vermis in child offspring of parents with bipolar disorder.
Topics: Adolescent; Aspartic Acid; Bipolar Disorder; Brain Chemistry; Cerebellum; Child; Choline; Female; Hu | 2011 |
Association of the brain-derived neurotrophic factor val66met polymorphism with magnetic resonance spectroscopic markers in the human hippocampus: in vivo evidence for effects on the glutamate system.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Creatine; Female; Genetic | 2012 |
Neurochemical alteration in the caudate: implications for the pathophysiology of bipolar disorder.
Topics: Adolescent; Adult; Antidepressive Agents; Aspartic Acid; Bipolar Disorder; Brain Mapping; Caudate Nu | 2011 |
Large positive effect of lithium on prefrontal cortex N-acetylaspartate in patients with bipolar disorder: 2-centre study.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Cost of Illness; Female; Humans; Image Processing, Computer- | 2012 |
In vivo glutathione levels in young persons with bipolar disorder: a magnetic resonance spectroscopy study.
Topics: Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Female; Glutathione; Human | 2013 |
Frontal lobe differences in bipolar disorder as determined by proton MR spectroscopy.
Topics: Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Choline; Female; Frontal Lobe; Humans; Magnetic | 2002 |
Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex.
Topics: Acute Disease; Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Female; Glutamic Acid; Glu | 2003 |
Lower concentration of hippocampal N-acetylaspartate in familial bipolar I disorder.
Topics: Adult; Ambulatory Care; Aspartic Acid; Axons; Bipolar Disorder; Choline; Creatine; Family; Functiona | 2003 |
Neuronal pathology in the hippocampal area of patients with bipolar disorder: a study with proton magnetic resonance spectroscopic imaging.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Female; Hippocampus; Humans; Magnetic Resonance Spectroscopy | 2003 |
N-acetylaspartate and N-Acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study.
Topics: Aspartic Acid; Autopsy; Biomarkers; Bipolar Disorder; Case-Control Studies; Chromatography, High Pre | 2003 |
Proton magnetic resonance spectroscopy of bipolar disorder versus intermittent explosive disorder in children and adolescents.
Topics: Adolescent; Age Factors; Aspartic Acid; Bipolar Disorder; Child; Choline; Creatine; Diagnosis, Diffe | 2003 |
Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals.
Topics: Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Brain Mapping; Choline; Creatine; Depressive Dis | 2003 |
Hippocampal neurochemical pathology in patients at first episode of affective psychosis: a proton magnetic resonance spectroscopic imaging study.
Topics: Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Cerebral Cortex; Choline; Creatine; Depressive D | 2004 |
A proton magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in acute mania.
Topics: Acute Disease; Adult; Antimanic Agents; Antipsychotic Agents; Aspartic Acid; Bipolar Disorder; Choli | 2005 |
1H magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in bipolar disorder patients.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Creatine; Diagnostic and Statistical M | 2005 |
Reduced NAA levels in the dorsolateral prefrontal cortex of young bipolar patients.
Topics: Adolescent; Adult; Age Factors; Aspartic Acid; Bipolar Disorder; Child; Choline; Creatine; Female; H | 2005 |
N-acetylaspartate levels in bipolar offspring with and at high-risk for bipolar disorder.
Topics: Adolescent; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Child; Cohort Studies; Creatine; | 2005 |
Hippocampal 1H MRS in first-episode bipolar I patients.
Topics: Adult; Analysis of Variance; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Choline; Creatin | 2006 |
Low cerebrospinal fluid glutamate and glycine in refractory affective disorder.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Ch | 2007 |
A 1HMRS study of the anterior cingulate gyrus in euthymic bipolar patients.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Female; Gyrus Cinguli; Humans; Lithium; M | 2006 |
Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects.
Topics: Adult; Aged; Analysis of Variance; Aspartic Acid; Bipolar Disorder; Brain Mapping; Depressive Disord | 2007 |
Tryptophan breakdown pathway in bipolar mania.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Brief Psychiatric Rating Scale; Female; Gyrus Cinguli; Human | 2007 |
Reduced concentrations of N-acetylaspartate (NAA) and the NAA-creatine ratio in the basal ganglia in bipolar disorder: a study using 3-Tesla proton magnetic resonance spectroscopy.
Topics: Adult; Aspartic Acid; Basal Ganglia; Bipolar Disorder; Creatine; Female; Hospitalization; Humans; Ma | 2007 |
Abnormal cellular energy and phospholipid metabolism in the left dorsolateral prefrontal cortex of medication-free individuals with bipolar disorder: an in vivo 1H MRS study.
Topics: Adult; Analysis of Variance; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Creatine; Energy | 2007 |
Measuring mania metabolites: a longitudinal proton spectroscopy study of hypomania.
Topics: Adult; Affect; Aspartic Acid; Basal Ganglia; Bipolar Disorder; Brain Mapping; Choline; Energy Metabo | 2007 |
Low levels of N-acetyl aspartate in the left dorsolateral prefrontal cortex of pediatric bipolar patients.
Topics: Adolescent; Aspartic Acid; Bipolar Disorder; Child; Creatine; Female; Glycerylphosphorylcholine; Hum | 2007 |
Brain-derived neurotrophic factor val66met polymorphism affects prefrontal energy metabolism in bipolar disorder.
Topics: Adult; Amino Acid Substitution; Aspartic Acid; Bipolar Disorder; Brain-Derived Neurotrophic Factor; | 2007 |
Dorsolateral prefrontal N-acetyl-aspartate concentration in male patients with chronic schizophrenia and with chronic bipolar disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Cerebrospinal Fluid; Choline; Chronic Disease; Creatine; Fou | 2007 |
Dopamine transporter genotype influences N-acetyl-aspartate in the left putamen.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Dominance, Cerebral; Dopamine Plasma Memb | 2009 |
Metabolic alterations in medication-free patients with bipolar disorder: a 3T CSF-corrected magnetic resonance spectroscopic imaging study.
Topics: Adolescent; Adult; Aspartic Acid; Basal Ganglia; Bipolar Disorder; Brain; Case-Control Studies; Caud | 2008 |
Neurochemical pathology in hippocampus in euthymic patients with bipolar I disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Dysthymic Disorder; Female; Hippocampus; | 2008 |
Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder.
Topics: Adult; Analysis of Variance; Animals; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Case-Contro | 2009 |
Glutamate as a spectroscopic marker of hippocampal structural plasticity is elevated in long-term euthymic bipolar patients on chronic lithium therapy and correlates inversely with diurnal cortisol.
Topics: Adult; Aged; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Choline; Circa | 2009 |
Biochemical changes in the cingulum in patients with schizophrenia and chronic bipolar disorder.
Topics: Adult; Analysis of Variance; Aspartic Acid; Bipolar Disorder; Choline; Chronic Disease; Creatine; Fe | 2008 |
Temporal change in N-acetyl-aspartate concentrations in adolescents with bipolar depression treated with lithium.
Topics: Adolescent; Affect; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Child; Dominance, Cerebral; F | 2008 |
[Lithium aspartate in drug dependence].
Topics: Adult; Alcoholism; Aspartic Acid; Bipolar Disorder; Female; Humans; Lithium; Male; Middle Aged; Subs | 1982 |
Quantitative proton magnetic resonance spectroscopy of the basal ganglia in patients with affective disorders.
Topics: Adult; Aspartic Acid; Basal Ganglia; Bipolar Disorder; Choline; Creatine; Depressive Disorder; Femal | 1998 |
Proton magnetic resonance spectroscopy of the lenticular nuclei in bipolar I affective disorder.
Topics: Adult; Age Factors; Aspartic Acid; Bipolar Disorder; Brain Mapping; Cell Survival; Choline; Corpus S | 1998 |
Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Female; Functional Laterality; Humans; Magnetic Resonance Sp | 2000 |
Proton MR spectroscopy in children with bipolar affective disorder: preliminary observations.
Topics: Aspartic Acid; Basal Ganglia; Bipolar Disorder; Child; Choline; Creatine; Energy Metabolism; Frontal | 2000 |
Increased thalamic N-acetylaspartate in male patients with familial bipolar I disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Humans; Hypertrophy; Magnetic Resonance S | 2001 |
Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients.
Topics: Adult; Aspartic Acid; Basal Ganglia; Bipolar Disorder; Choline; Creatine; Depressive Disorder; Energ | 1992 |
The human brain resonance of choline-containing compounds is similar in patients receiving lithium treatment and controls: an in vivo proton magnetic resonance spectroscopy study.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Brain; Choline; Corpus Callosum; Humans; Lithium Carbonate; | 1992 |
[Is lithium aspartate at low serum levels more effective than the usual lithium salts?].
Topics: Adult; Aspartic Acid; Bipolar Disorder; Dose-Response Relationship, Drug; Erythrocytes; Humans; Kine | 1986 |
Plasma concentrations of tryptophan and other amino acids in manic-depressive patients.
Topics: Alanine; Arginine; Aspartic Acid; Bipolar Disorder; Emotions; Glutamates; Glycine; Humans; Isoleucin | 1974 |
[Clinical administration of lithiumaspartate].
Topics: Acetates; Administration, Oral; Adolescent; Adult; Aspartic Acid; Biopharmaceutics; Bipolar Disorder | 1974 |
Medical research council unit for metabolic studies in psychiatry, Sheffield.
Topics: Amino Acid Metabolism, Inborn Errors; Aspartic Acid; Bipolar Disorder; Catatonia; Circadian Rhythm; | 1973 |